[ET Net News Agency, 24 November 2021] Shanghai Henlius Biotech, Inc. (02696) said the
filing of clinical trial for HLX301 (recombinant humanised anti-PD-L1 and anti-TIGIT
bispecific antibody injection) independently developed by the company for the treatment of
locally advanced or metastatic solid tumours (HLX301) has been acknowledged by Therapeutic
Goods Administration, Australia, and the Phase 1 clinical trial is permitted to commence
in Australia (CTN No.: CT-2021-CTN-04658-1).
The Phase 1 clinical study of the project in Australia is intended to be initiated in
the near future. (RC)